Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...
Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback